Laurie Stelzer
Director/Board Member at PMV PHARMACEUTICALS, INC.
Net worth: - $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David Mack | M | 62 | 11 years | |
Jeffrey Henderson | M | 59 | 9 years | |
Cameron Turtle | M | 34 | 1 years | |
Carol Gallagher | M | 59 | 2 years | |
Michael Carulli | M | 74 | 4 years | |
Arnold Levine | M | 84 | 11 years | |
Robert Ticktin | M | 62 | - | |
Heidy Abreu King-Jones | F | 41 | 1 years | |
Kirsten Flowers | F | 49 | 2 years | |
Michael Henderson | M | 34 | 1 years | |
Richard Heyman | M | 66 | 4 years | |
Scott Burrows | M | 47 | 1 years | |
Bernadette Connaughton | F | 65 | 6 years | |
Brian Goodman | M | - |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | - |
Charles Baum | M | 65 | 3 years | |
Deepika Jalota | M | 48 | 5 years | |
Tomas Kiselak | M | 37 | 1 years | |
Timothy J. Smith | M | - | 3 years | |
Tyler Jacks | M | 63 | 12 years | |
Amit Munshi | M | 56 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | - |
Peter Harwin | M | 38 | 1 years | |
Lauren Harshman | F | - | 3 years | |
Deanna Nguyen | M | - | 1 years | |
Marc Fellous | M | - | 2 years | |
Mira Huyghe | F | - | 1 years | |
Crystal Zuckerman | F | - | 4 years | |
Shibu Sleeba | M | - | 4 years | |
Laura De Leon | F | - | 5 years | |
Joshua Friedman | M | - | 1 years | |
Ciaran Lawlor | M | - |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | 3 years |
Amy Marinne Fox | F | - | 4 years | |
Lamine Mbow | M | - | 3 years | |
Steve Knowles | M | - | 6 years | |
Paul Fehlner | M | 61 | 1 years | |
Mark Mckenna | M | 44 | - | |
Binh Vu | M | 56 | - | |
Scott W. Rowlinson | M | 56 | 10 years | |
Jeffrey Albers | M | 52 | 1 years | |
Matt Roden | M | 53 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | 1 years |
Morana Jovan-Embiricos | M | 57 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | - |
Brian Connolly | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
J. Goater | M | 48 | 6 years | |
Dave Grayzel | M | 56 | 9 years | |
Kathryn Falberg | F | 63 | 9 years | |
David Ramsay | M | 59 | 12 years | |
Vickie Reed | F | 62 | 9 years | |
Masaru Matsuda | M | 53 | 3 years | |
Harry Leonhardt | M | 67 | 5 years | |
Winston Kung | M | 48 | 7 years | |
Liisa I. Nogelo | F | 53 | - | |
Michael Paolucci | M | 64 | 5 years | |
Benjamin Hickey | M | 50 | 5 years | |
Russell Cox | M | 60 | 9 years | |
Jessica Fees | F | 52 | 8 years | |
Denice Torres | F | 64 | 2 years | |
David Meek | M | 59 | 2 years | |
Craig Shepherd | M | - | 7 years | |
Thilo Schroeder | M | 42 | 3 years | |
Robert Azelby | M | 56 | 5 years | |
Randal Kirk | M | 70 | 11 years | |
Homa Yeganegi | F | - | - | |
Nawal Ouzren | F | 45 | 1 years | |
Temre Johnson | M | - | 5 years | |
Katharine Knobil | M | 60 | 2 years | |
Joan Schmidt | F | 60 | - | |
Ramy Ibrahim | M | 49 | 4 years | |
Thomas Heineman | M | - | 2 years | |
Theresa R. Boni | F | 56 | - | |
Albert Kildani | M | - | - | |
Aaron Ondrey | M | 48 | 2 years | |
George Morrow | M | 72 | 10 years | |
Alison Lawton | F | 62 | 4 years | |
William J. Fallon | M | - | 14 years | |
Peter Thompson | M | 64 | 8 years | |
Randall E. Woods | M | 72 | 13 years | |
Frederick Gluck | M | 88 | 13 years | |
Jim Mazzola | M | - | 3 years | |
Manmeet Singh Soni | M | 46 | 3 years | |
Charles Sigal | M | 72 | 5 years | |
Christopher Cabell | M | 54 | 3 years | |
Henry Fuchs | M | 66 | 11 years | |
Cameron McDonough | M | 53 | 4 years | |
Seth D. Lewis | M | - | - | |
Steven W. Spector | M | 59 | 19 years | |
Armen Shanafelt | M | 64 | 9 years | |
Steven Galson | M | 67 | - | |
James Daly | M | 63 | 9 years | |
Daniel Lynch | M | 65 | 5 years | |
Deborah Wenkert | M | 65 | 6 years | |
Chandra Adams | F | - | 2 years | |
Roy Baynes | M | 69 | 10 years | |
Daniel Billen | M | 70 | 7 years | |
Robert Coffin | M | 58 | 2 years | |
Jonathan Peacock | M | 66 | 4 years | |
Iain Dukes | M | 65 | 3 years | |
Shamim Ruff | F | 64 | 4 years | |
Brandon Smith | M | 50 | 7 years | |
Robert Steven Sikorski | M | - | 4 years | |
Ian Leitch | M | 60 | 5 years | |
Ellen Feigal | M | 69 | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Laurie Stelzer
- Personal Network